image image
Jean's Story

Morgellons Diary

December 2009 after a return trip for Thanksgiving Holiday with family my scalp started itching intensely day & night. Went to the walk in clinic & saw physician. He said problem more than likely was just an allergy reaction to a shampoo or hair product. Gave me a topical solution "Clobetasol Propionate” and told to apply when itching.

Read the full story

Herminia's story

...Week 2

On the second week of my treatment, I have seen a bit of a change in my skin. Dark patches on my skin have started to clear up. I am still very itchy and my back has a lot of bump that are healing slowly. Everything below my thighs to my feet are also showing signs of healing. The lesions are deeper like you told me.


Read the full story

Dr. Rahim Karjoo M.D., F.A.S.C.P.

Doctor Karjoo is offering a free initial consultation to sufferers of this real condition.

You may always contact our office at

(888) RKarjoo

(714) 636-0261  & (714) 636-0211


Qualifying for treatment is the first step in winning your battle with Morgellons

Please fill out the free questionnaire and supply the correct email address and phone number;

Dr. Karjoo or one of his associates will contact you directly via the contact information you provide.

Morgellons Research

I Doctor Karjoo have made amazing discoveries in Morgellons patients. There is real suffering in these patients. I am able to treat and help return patients to a normal life style.

My current Research on Morgellons may be viewed from the listings in the side bar at the left.

Research on Morgellons is ongoing and I plan to submit follow up studies as they become available. There is increasing interest in this study as more and more, long time sufferers of these symptoms contact me looking for answers.

If you have any questions about my research or the details in this article please contact me at my office at (714) 636-0261


Rahim Karjoo, MD



The term “Morgellons” was coined in 2002 by a woman name Mary Leiato, whose young boy suffered a rash and ulcer around his mouth, combined with fibers that protruded from his skin. When this issue became prominent on the Internet, a lot of people rushed to the clinics and told physicians that they were suffering from Morgellons disease. This terminology was not known in the medical community and the presentation of the patients was very bizarre; the medical community, therefore, did not understand what they were dealing with. Many physicians refused to accept these patients, and no Morgellons disease treatment was offered. Some physicians labeled them as delusional or psychotic and referred them to a psychologist. After a while, many victims became hopeless, losing their jobs and families; ultimately, a few even became suicidal.

In 800 B.C., the first Persian physician, Zakaria Razi said that any human disease should be first given a name and terminology according to physical and historical findings, then researched by the experts and scientists until they find the cause and present it to the medical community. The final step is finding the treatment and following up with the patient.

In the 21st century, with all of our vaunted medical knowledge, state-of-the-art facilities, and capable researchers, combined with donations and centers for discovery of unknown diseases, we have still accepted this term Morgellons with no research or proof. We are long past due for proper research and treatment. Dr. Rahim Karjoo has been aware of this skin phenomenon and its cause since the early 1990s. He has clearly demonstrated that this skin phenomenon is due to the toxicity of silicone silica, both endogenous and exogenous. While he was reviewing hundreds of cases of silicone breast implants for women, he discovered skin lesions, as well as other general signs and symptoms identical to those exhibited by victims of this so-called Morgellons disease. 10% of recent Morgellon’s cases involved endogenous silicone implants. Three weeks after removing breast implants, patient’s skin healed, and “Karjoo’s Phenomenon” disappeared.

Dr. Karjoo states: “I am in the process of publishing my work on this subject. Victims of this condition, as well as the medical community at large, will see that this ‘unknown skin phenomenon’ is actually a known skin phenomenon.”
The result of this presentation is to change the name of “Morgellons” to Skin Phenomenon of granulomatous dermatoses due to toxicity of foreign body material with sub groups of perforating disorder collangenosis, perforating folliculitis, ellastosis perforans serpiginosa, and folliculitis in cutem penetras. The histopathology and clinical presentation of this skin phenomenon is in the process of being presented in a Dermatology and Environmental publication. The toxicity of silicone silica also will be addressed in an Environmental publication.
Further detail and information refer to (

Table 8.2 Dermatology book of Phillip H. Mckee Turn edition Volume I
Important causes of foreign body granulomata

Table 8.2 Dermatology book of Phillip H. Mckee Turn edition Volume I

Karjoo’s Skin Phenomenon and Treatment.

Zakaria Razi2 (864 A.D.) was the preeminent pharmacist and physician of his time
Full name Muhammad ibn Zakariya Razi
Born August 26, 865 Rey, Persia
Died 925
Era Medieval era
Region Persia
School Persian science
Main interests Chemistry, Medicine, Biology


1. Muhammad ibn Zakariya al-Razi-Wikipedia, the free encyclopedia.
2. Silicone breast implants and illness – Breast implants forum, The Light Party, Health Peace and Freedom for All.
3. United state environmental protection agency pesticides and toxic substances – silicone dioxide and silica gel. September 1991.
4. Breast Implant Removal Without replacement Example – Insurance Coverage. 1996-2008 John Di Saia, MD… an Orange County California Plastic Surgeon.
5. Silica binding and toxicity in alveolar macrophages. Raymond F. Hamilton, Jr., Sheetal A. Thakur, and Andrij Holian.
6. Silicone Breast Implants and Injections over 300 patients with chronic ill health following silicone breast implants or injections. From Doctor Myhill.
9. Moisse, Katie. “Morgellons: Mysterious Skin Disease Under Microscope.” Yahoo! News. Abc news, Thu, Jan 26, 2012. Web. 27 Jan. 2012


10. Mehregan, A.H., Schwartz, O.D., Livinggood, C.S. (1967) Reactive perforating collagenosis. Arch Dermatol, 96, 277-282.
11. Patterson, J.W. (1984) The perforating disorders. J Am Acad Dermatol, 10, 561-581.
12. Weiner, A.L. (1970) Reactive perforating collagenosis. Arch Dermatol, 102, 540-544.
13. Faver, I.R., Daoud, M.S., Su, W.P. (1994) Acquired reactive perforating collagenosis. Report of six cases and review of the literature. J Am Acad Dermatol, 30, 575-580.
14. Kanan, M.W. (1974) Familial reactive perforating collagenosis and intolerance to cold. Br. J Dermatol, 91, 405-414.
15. Nair, B.K.H., Sarojini, P.A., Basheer, A.M. et al (1974) Reactive perforating collagenosis. BR J Dermatol, 91, 399-403.
16. Kumar V., Mehndiratta, V., Sharma, R.C. et al (1998) Familial reactive perforating collagenosis: a case report. J Dermatol, 25, 54-56.
17. Kyriaki, A., Ephtichia, Z., Anna L. et al (1997) Reactive perforating collagenosis and acquired perforating dermatosis: presentation of two cases. J Dermatol, 24, 170-173.
18. Tay, Y.K., Weston, W.I., Aeling, J.L. (1996) Reactive perforating collagenosis in Teacher Collins syndrome. J, Am Acad Dermatol, 35, 982-983.
19. Iwamoto, I., Baba, S., Suzuki, H. (1998) Acquired perforating collagenosis with IgA nephropathy. Cases that meet Faver’s criteria. Br J Dermatol, 140, 521-524.
20. Kawakami, T., Saito, R. (1999) Acquired perforating collagenosis of diabetes mellitus: eight cases that meet Faver’s criteria. Br J Dermatol, 140, 521-524.
21. Cochrane, R.J., Tucker, S.B., Wilkin J.K. (1983) Reactive perforating collagenosis of diabetes and renal failure. Cutis, 31, 55-58.
22. Chae, K.S., Park, Y.M., Cho, S.H. et al (1998) Reactive perforating collagenosis associated with periampullary carcinoma. Br J Dermatol, 139, 548-550.
23. Bong, J.L., Fleming, C.J., Kemmett, D. (2000) Reactive perforating collagenosis associated with underlying malignancy. Br J Dermatol, 142, 390-391.
24. Mahanupab, P., Chiewchanvit, S. (2002) Acquired reactive perforating collagenosis: report of a case and review of the literature. J Med Assoc Thai, 85, 1019-1023.
25. Basak, P.Y., Turkmen, C. (2001) Acquired reactive perforating collagenosis. Eur J Dermatol, 11 466-468.
26. Tang, W.Y., Chong, L.Y., Lam, S.Y. et al (1995) Acquired reactive perforating collagenosis in two Chinese patients. Int J Dermatol, 34, 196-198.
27. Briggs, P.L., Fraga, S. (1995) Reactive perforating collagenosis of diabetes mellitus. J Am Acad Dermatol, 32, 521-523.
28. Satchell, A.C., Crotty, K., Lee, S. (2001) Reactive perforating collagenosis: a condition that may be underdiagnosed. Australas J Dermatol, 42, 284-287.
29. Morton, C.A., Henderson, I.S., Jones, M.C. et al (1997) Acquired perforating collagenosis in British dialysis population. Br J Dermatol, 137, 472-473.


30. Zanardo, L., Stolz W., Landhaler, M. et al (2001) Reactive perforating collagenosis after disseminated zoster. Dermatology, 203, 273-275.
31. Lee, H.N., Lee, D.W., Lee, J.Y. et al (2001) Two cases of reactive perforating collagenosis arising at the site of healed herpes zoster. Int J Dermatol, 40, 191-192.
32. Bang, S.W., Kim, Y.K., Whank, K.U. (1997) Acquired reactive perforating collagenosis: unilateral umbilicated papules along the lesions of herpes zoster. J Am Acad Dermatol, 36, 778-779.
33. Kurschal, P., Kroger, A., Scharffetter-Kochanek, K. et al (2000) Acquired reactive perforating collagenosis triggered by scabies infection. Acta Derm Venerol, 80, 384-385.
34. Bank, D.E., Cohen, P.R., Kohn, S.R. (1989) Reactive perforating collagenosis in a setting of double disaster: acquired immunodeficiency syndrome and end-stage renal disease. J Am Acad Dermatol, 21, 371-374.
35. Nakanishi, G., Tsunemitsu, R., Akagi, O. (1999) Reactive perforating collagenosis occurring in a zosteriform distribution. Br J Dermatol, 141, 367-369.
36. Cohen, R.W., Auerbach, R. (1989) Acquired reactive perforating collagenosis. J Am Acad Dermatol, 20, 287-289.
37. Oziemski, M.A., Billson, V.R., Crostwaite, G.L. et al (1991) A new treatment for acquired reactive perforating collagenosis. Australas J Dermatol, 32, 71-74.
38. Trattner, A., Ingber, A., Sandbank, M. (1991) Mucosal involvement in reactive perforating collagenosis. J Am Acad Dermatol, 25, 1079-1082.
39. Yanahigara, M., Fujita, T., Shirasaki, A. et al (1996) The pathogenesis of the transepithelial elimination of the collagen bundles in acquired reactive perforating collagenosis. A light and electron microscopical study. J Cutan Pathol, 23, 398-403.
40. Herzinger, T., Schirren, C.G., Sander, C.A. et al (1996) Reactive perforating collagenosis – transepidermal elimination of type IV collagen. Clin Exp Dermatol, 21, 279-282.
41. Fretzin, D.F., Beal, D.W., Joa, W. (1980) Light and ultrastructural study of reactive perforating collagenosis. Arch Dermatol, 116, 1054-1058.


42. Mehregan, A.H., Coskey, R.J. (1968) Perforating folliculitis. Arch Dermatol, 97, 394-399.
43. Combermale, P., Courtois, D., Chouvet, B. (1990) Perforating folliculitis. Ann Dermatol Venereol, 117, 515-520.
44. Schgal, V.N., Jain, S., Thappa, D.M. et al (1993) Perforating dermatoses: a review and report of four cases. J Dermatol, 20, 329-340.
45. Hurwitz, R.M. (1985) The evolution of perforating folliculitis in patients with chronic renal failure. Am J Dermatopathol, 7, 231-239.
46. White, R.C. Jr, Heskel, N.S., Pokorny, D.J. (1982) Perforating folliculitis of hemodialysis. Am J Dermatopathol, 4, 109-116.
47. Chang, P., Fernandez, VV. (1993) Acquired perforating disease: report of nine cases. Int J Dermatol, 32, 874-876.
48. Rubio, F.A., Herranz, P., Robayna, G. et al (1999) Perforating folliculitis: report of case in an HIV-infected man. J Am Acad Dermatol, 40, 300-302.
49. Saldanha, L.F., Gonick, H.C., Rodriguez, H.J. et al (1997) Silicon-related syndrome in dialysis patients. Nephron, 77, 48-56.
50. Kahana, M., Trau, h., Dolev, E. et al (1985) Perforating folliculitis in association with primary sclerosing cholangitis. Am J Dermatopathol, 7, 271-276.
51. Mehregan, A.H. (1968) Elastosis perforans serpiginosa: a review of the literature and report of 11 cases. Arch Dermatol, 97, 381-393.
52. Pedro, S.D., Garcia, R.L. (1974) Disseminate elastosis perforans serpiginosa, Arch Dermatol, 109, 84-85.
53. Rios-Buceta, I., Amigo-Echenagusta, A., Sols-Candelas, M. et al (1993) Elastosis perforans serpiginosa with simultaneous onset in two sister. Int J Dermatol, 32, 879-881.
54. Armstrong, D.K., Walsh, M.Y., Allen, G.E. (1997) Elastosis perforans serpiginosa associated with unilateral atrophoderma of Pasini and Pierini in an individual with 47 XYY karyotype. Br J Dermatol, 137, 158-160.
55. Whyte, H.J., Winkelmann, R.K. (1960) Elastosis perforans (perforating elastosis). The association of congenital abnormalities, salient facts in the histology, studies of enzyme digestion and a report of a necropsy in a case. J Invest Dermatol, 35, 113-122.
56. Sahn, E.E., Maize, J.C., Garen, P.D. et al (1989) D-penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. J Am Acad Dermatol, 20, 979-988.
57. O’Donnell, B., Kelly, P., Dervan, P. et al (1992) Generalized elastosis perforans serpiginosa in Down’s syndrome. Clin Exp Dermatol, 17, 31-33.
58. Mehta, R.K., Burrows, N.P., Payne, C.M. et al (2001) Elastosis perforans serpiginosa and associated disorders. Clin Exp Dermatol, 26, 521-524.
59. Schepis, C., Barone, C., Siragusa, M. et al (2002) An updated survey on skin conditions in Down syndrome. Dermatology, 205, 234-238.
60. De Pasquale, R., Nasca, M.R., Musumeci, M.I. et al (2002) Elastosis perforans serpiginosa in an adult with Down’s syndrome: report of a case with symmetrical localized involvement. J Eur Acad Dermatol Venereol, 16, 387-389.
61. Dourmishev, A., Miteva, I., Mitev, V. et al (2000) Cutaneous aspects of Down syndrome. Cutis, 66, 420-424.
62. Stragusa, M., Romano, C., Cavallari, V. et al (1997) Localized elastosis perforans serpiginosa in a boy with Down syndrome. Pediatr Dermatol, 14, 244-246.
63. Kirsch, n., Hukill, P.B. (1997) Elastosis perforans serpiginos induced by penicillamine. Arch Dermatol, 113, 630-635.
64. Pass, F., Goldfischer, S., Sternlies, I. et al (1973) Elastosis perforans serpiginosa during penicillamine therapy for Wilson’s disease. Arch Dermatol, 108, 713-715.
65. Deguti, M.M., Mucenic, M., Cancado, E.L. et al (2002) Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson’s disease patient. Am J Gastroenterol, 97, 2153-2154.
66. Hill, V.A., Seymour, C.A., Mortimer, P.S. (2000) Penicillamin-induced elastosis perforans serpiginosa and cutis laxa in Wilson’s disease. Br J Dermatol, 142, 560-561.
67. Iozumi, K., Nakagawa, H., Tamaki, K. (1997) Penicillamin-induced degenerative dermatoses: report of a case and brief review of such dermatoses. J Dermatol, 24, 458-465.
68. Langeveld-Wildshut, E.G., Toonstra, J., van Vloten, W.A., Beemer, F.A. (1993) Familial elastosis perforans serpiginosa. Arch Dermatol, 129, 205-207.
69. Cohen, A.S., Hashimoto, K. (1960) Electron microscopic observations on the leion of elastosis perforans serpiginosa. J Invest Dermatol, 35, 15-19.
70. Fujimoto, N., Akagi, A., Tajima, S. et al (2002) Expression of the 67-kDa elastin receptor in perforating skin disorders. Br J Dermatol, 146, 74-79.


71. Fujimoto, N., Tajima, S., Ishibashi, A. (2000) Elastin peptides induce migration and terminal differentiation of cultured keratinocytes via 67 kDa a elastin receptor in vitro: 67 kDa a elastin receptor is expressed in the keratinocytes eliminating elastic materials in elastosis perforans serpiginosa. J Invest Dermatol, 115, 633-639.
72. Carter, V.H., Constantine, V.S. (1968) Kyrle’s disease. I. Clinical findings in five cases and review of the literature. Arch Dermatol, 97, 624-632.
73. Moss, H.V. (1979) Kyrle’s disease. Cutis, 23, 463-466.
74. Pajarre, R., Alavaikko, M. (1973) Kyrle’s disease. Hyperkeratosis follicularis et parafollicularis in cutem penetrans. Acta Derm Venereol, 53, 505-508.
75. Powell, E.W. (1970) Hyperkeratosis follicularis et parafollicularis in cutem penetrans (? Kyrle’s disease). Br J Dermatol, 83, 420-422.
76. Tessler, H.H., Apple, D.J., Golberg, M.F. (1973) Ocular findings in a kindred with Kyrle disease. Hyperkeratosis follicularis et parafollicularis in cutem penetrans. Arch Ophthalmol, 90, 278-280.
77. Hood, A.F., Hardengen, G.L., Zarate, A.R. et al (1982) Kyrle’s disease in patients with chronic renal failure. Arch Dermatol, 118, 85-88.
78. Salomon, R.J., Baden, T.J., Gammon, W.R. (1986) Kyrle’s disease and hepatic insufficiency. Arch Dermatol, 112, 18-19.
79. Kossard, E., Palmer, G., Constance, T.J. (1970) Coexistence of hyperkeratosis lenticularis perstans (Flegel) and hyperkeratosis follicularis et parafollicularis in cutem penetrans (Kyrle) in a patient. Acta Derm Venereol, 50, 385-390.
80. Constantine, V.S., Carter, V.H. (1968) Kyrle’s disease. II. Histopathologic findings in five cases and review of the literature. Arch Dermatol, 97, 633-639.
81. Ford, T.C., Mirachi, J.A., Castillo, J. (1990) Kyrle’s disease. A rare case report and surgical treatment. J Am Pediatr Med Assoc, 80, 151-155.
82. Sorhage, B., Glowania, H.J., Schafer, R. (1990) Kyrle disease – a case report. Z Hautkr, 65, 847-850.
83. Hicks, J., Carpenter, C.L., Reed, R.J. (1979) Periumbilical perforating pseudoxanthoma elasticum. Arch Dermatol, 115, 300-303.
84. Karp, D.L., O’Neill, M.S., Haberman, A.L. et al (1996) A yellow plague with keratotic papules on the abdomen. Perforating calcific elastosis (periumbilical perforating pseudoxanthoma elasticum [PXE], localized acquired cutaneous PXE). Arch Dermatol, 132, 224-225, 227-228.
85. Pruzan, D., Rabbin, P.E., Heilman, E.R. (1992) Periumbilical perforating pseudoxanthoma elasticum. J Am Acad Dermatol, 26, 642-644.
86. Toporcer, M.B., Kantor, G.R. (1990) Periumbilical hyperpigmented plaque. Periumbilical perforating pseudoxanthoma elasticum (PPPXE). Arch Dermatol, 126, 1639, 1642.
87. Kazakis, A.M., Parish, W.R. (1988) Periumbilical perforating pseudoxanthoma elasticum. J Am Acad Dermatol, 19, 384-388.
88. Nickoloff, B.J., Noodleman, F.R., Abel, E.A. (1985) Perforating pseudoxanthoma elasticum associated with chronic renal failure and hemodialysis. Arch Dermatol, 121, 1321-1322.
89. Kazakis, A.M., Parish, W.R. (1988) Periumbilical perforating pseudoxanthoma elasticum. J Am Acad Dermatol, 19, 384-388.
90. Somasundaram, V., Premalatha, S., Rao, N.A. et al (1987) Periumbilical perforating pseudoxanthoma elasticum. Int J Dermatol, 26, 536-537.


Morgellons Disease Research

The following contents were written by third parties for general educational information on Morgellons disease. Dr. Karjoo and Morgellons Medical Center were not involved in the writing or production of these contents. To get more information on Morgellons, the research about this disease and treatment options, please contact our office and set up a Morgellons disease treatment consultation.

Morgellons disease is a condition that affects the hair as well as the hair follicle leading to a lot of changes in the structure of the hair and the follicle. It can lead to the spread of infection as well as other changes that are also accompanied by inflammation, ulceration, and infection of the skin. In 85% of the cases, renowned Morgellons disease research specialist Dr. Rahim Karjoo found a strong presence of particles such as silica, silicone, and polyurethane on the skin’s surface, as well as in the deeper layers of the skin.

Patients who visit Dr. Karjoo’s facility are asked to obtain hair samples as well as a biopsy of the skin lesions, which are then checked at the lab for Morgellons disease. In most of the cases, microscopic examination reveals that there are very obvious changes to the hair filament with varying thickness, color, and other abnormal changes in the hair shaft as well as hair follicle. Most patients also suffered from abscess formation, ulceration, and fungi. The skin’s surface showed a strong presence of silica or silicone particles, which also penetrated the skin.
Based on the extensive Morgellons disease research conducted by Dr. Karjoo, it is clear that this illness is caused by the nanoparticle silica and this leads to unusual skin and hair conditions, known as ‘Karjoo’s phenomenon.’ A lot of information is available based on years of research by Dr. Karjoo. Studies have been conducted on toxicity and diseases that are caused primarily due to the presence of these silica nanoparticles.

Dr. Karjoo is a board certified chief pathologist with years of experience in treating patients with Morgellons disease. He has found the root cause of this distressing situation and has successfully treated patients who suffer with this condition.
The latest Morgellons disease research shows that this is a condition that can be cured, allowing patients the freedom to get back to a normal life. So, if you have noticed such symptoms, you should contact Dr. Karjoo at his Garden Grove Clinic, CA, for a free consultation.






Rahim Karjoo, MD, FCAP, FASCP

12665 Garden Grove Blvd
Suite 111 & 113

Garden Grove, CA 92843

Phone: (714) 636-0261

[email protected]
Office Hours 8:00am to 5:00pm
Monday - Friday PDT

Call now for a free consultation!

Social Bookmarking